Peripheral Neuropathy Affects 1% of Adults Worldwide, Diabetes Leading Cause

Peripheral neuropathy represents a significant global health challenge, affecting approximately 1% of adults worldwide with symptoms ranging from mild numbness to wheelchair-requiring disability. This condition involves damage to peripheral nerves and has over 200 identified causes.

Diabetes emerges as the dominant cause, accounting for more than 50% of peripheral neuropathy cases in Western populations and affecting approximately 206 million people globally. The condition typically follows a length-dependent pattern, beginning in the longest nerve fibers (toes) and progressing proximally over time, primarily affecting sensory rather than motor function.

Beyond diabetes, other significant causes include hereditary conditions like Charcot-Marie-Tooth disease, medication toxicity from chemotherapy agents, vitamin B12 deficiency, and monoclonal gammopathies. Notably, up to 27% of cases remain idiopathic despite comprehensive diagnostic testing.

Treatment focuses primarily on symptom management rather than nerve regeneration. First-line therapies for neuropathic pain include gabapentin, pregabalin, duloxetine, and tricyclic antidepressants. However, treatment efficacy remains limited, with only 38% of patients achieving 50% pain reduction on gabapentin therapy.

The prognosis varies by underlying cause, but complete reversal of nerve damage remains uncommon. This highlights the critical need for preventive strategies, particularly diabetes management, and continued research into neuroprotective and regenerative therapies for this prevalent and often debilitating condition.